Stockscreener 앱 받기
17.53
0.46%
0.08
시간 외 거래:
17.53
전일 마감가:
$17.45
열려 있는:
$17.62
하루 거래량:
200.29K
Relative Volume:
0.81
시가총액:
$470.11M
수익:
$31.38M
순이익/손실:
$-6.69M
주가수익비율:
-67.42
EPS:
-0.26
순현금흐름:
$-1.84M
1주 성능:
-0.68%
1개월 성능:
+18.85%
6개월 성능:
-1.90%
1년 성능:
+15.48%
1일 변동 폭
$17.29
$18.23
1주일 범위
$16.68
$18.47
52주 변동 폭
$11.09
$23.00
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
명칭
Eton Pharmaceuticals Inc
전화
(847) 787-7361
주소
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
17.53 | 467.97M | 31.38M | -6.69M | -1.84M | -0.26 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.22 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
125.96 | 53.16B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.47 | 47.25B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.91 | 37.59B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
490.21 | 21.85B | 3.13B | 1.27B | 1.12B | 26.39 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 재확인 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | B. Riley Securities | Buy |
| 2025-01-06 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-05-06 | 개시 | Craig Hallum | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-01-04 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-20 | 개시 | B. Riley FBR | Buy |
| 2019-06-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
HC Wainwright Issues Pessimistic Outlook for ETON Earnings - MarketBeat
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026 - The Manila Times
Eton Pharmaceuticals Announces Fourth Quarter and Full Year 2025 Financial Results Date and Conference Call Details - Quiver Quantitative
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, ... - Bluefield Daily Telegraph
Eton inks deal to sell its 10th rare disease drug - Crain's Chicago Business
Craig Hallum Issues Positive Forecast for Eton Pharmaceuticals (NASDAQ:ETON) Stock Price - MarketBeat
Eton Pharmaceuticals price target raised to $30 from $29 at Craig-Hallum - TipRanks
Eton Pharmaceuticals acquires U.S. rights to hemangioma drug By Investing.com - Investing.com Canada
Eton Pharmaceuticals Acquires US Commercialization Rights to Pierre Fabre's Hemangeol - marketscreener.com
HC Wainwright Forecasts Strong Price Appreciation for Eton Pharmaceuticals (NASDAQ:ETON) Stock - MarketBeat
Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL - TipRanks
Eton Pharmaceuticals, Inc. announced that, in addition to the acquisition of core assets, the company also plans to purchase approximately $1.5 million worth of inventory products at the time of transaction closing. - Bitget
Understanding Momentum Shifts in (ETON) - Stock Traders Daily
Lumbard & Kellner LLC Buys New Holdings in Eton Pharmaceuticals, Inc. $ETON - MarketBeat
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - Benzinga
Only FDA-approved infantile hemangioma drug moves to Eton with $0 co-pays - Stock Titan
Eton Pharmaceuticals (NASDAQ: ETON) licenses U.S. HEMANGEOL rights in orphan drug deal - Stock Titan
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution - Sahm
Eton Pharmaceuticals' DESMODA Receives FDA Approval - Intellectia AI
US FDA approves Eton Pharma’s hormonal disorder drug - 1470 & 100.3 WMBD
Eton Pharmaceuticals Receives FDA Approval for New Drug Launch - Intellectia AI
Eton Reports US FDA Approval for Desmoda Oral Solution - marketscreener.com
Eton Pharmaceuticals Wins FDA Approval for DESMODA Therapy - TipRanks
Eton wins FDA nod for rare disorder therapy Desmoda (ETON) - Seeking Alpha
US FDA approves Eton's liquid therapy for rare water-balance disorder - Reuters
US FDA approves Eton Pharma's hormonal disorder drug - AOL.com
Eton Pharmaceuticals Launches DESMODA™, First FDA-Approved Oral Solution for Central Diabetes Insipidus - Quiver Quantitative
FDA clears first liquid desmopressin for rare water-balance disorder - Stock Titan
US FDA approves Eton’s liquid therapy for rare water-balance disorder - whbl.com
ETON Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
FDA To Decide On ET-600 On February 25: Will It Mark Eton's Ninth Commercial Product? - RTTNews
Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th - The Manila Times
Rare-disease drug maker Eton to meet attendees at Leerink conference - Stock Titan
February 2026's Top Growth Companies With Insider Influence - simplywall.st
Eton Pharmaceuticals submits NDA for its diabetes insipidus treatment - MSN
What are Eton Pharmaceuticals Inc.’s technical support levelsJuly 2025 Big Picture & Real-Time Stock Entry Alerts - mfd.ru
Volatility Watch: Is Eton Pharmaceuticals Inc a cyclical or defensive stockGap Up & Safe Entry Zone Identification - baoquankhu1.vn
Activity Recap: Is Eton Pharmaceuticals Inc. still a buy after recent gains - mfd.ru
Eton Pharmaceuticals (ETON) Investor Outlook: A Small-Cap Biotech with a 78.68% Potential Upside - DirectorsTalk Interviews
What drives Eton Pharmaceuticals Inc.’s stock priceEarnings Miss & Weekly High Potential Stock Alerts - mfd.ru
We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon - simplywall.st
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of "Hold" by Analysts - MarketBeat
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Average Rating of “Hold” by Analysts - Defense World
Analysts Are Bullish on These Healthcare Stocks: Eton Pharmaceuticals (ETON), HealthStream (HSTM) - The Globe and Mail
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug By Investing.com - Investing.com South Africa
Eton Pharmaceuticals stock rises after licensing ultra-rare disease drug - Investing.com India
Eton Pharmaceuticals Licenses US Marketing Rights to Ultra-Rare Disease Product - marketscreener.com
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate - Investing.com
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate - The Manila Times
Eton Pharmaceuticals licenses ultra-rare disease treatment candidate By Investing.com - Investing.com UK
Eton Pharmaceuticals Licenses U.S. Marketing Rights for Ultra-Rare Disease Product Candidate, Anticipates FDA Approval by Mid-2026 - Quiver Quantitative
Eton Pharmaceuticals Inc (ETON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.21%
1.77%
자본화:
|
볼륨(24시간):